Bristol-Myers Squibb Company
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
Last updated:
Abstract:
The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
Status:
Grant
Type:
Utility
Filling date:
11 Jan 2019
Issue date:
20 Sep 2022